Symbols / ZNTL
ZNTL Chart
About
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. The company develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. It also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 159.93M |
| Enterprise Value | -61.78M | Income | -149.32M | Sales | 26.86M |
| Book/sh | 3.50 | Cash/sh | 3.88 | Dividend Yield | — |
| Payout | 0.00% | Employees | 166 | IPO | — |
| P/E | — | Forward P/E | -1.36 | PEG | — |
| P/S | 5.95 | P/B | 0.71 | P/C | — |
| EV/EBITDA | 0.41 | EV/Sales | -2.30 | Quick Ratio | 7.55 |
| Current Ratio | 7.76 | Debt/Eq | 16.00 | LT Debt/Eq | — |
| EPS (ttm) | -2.08 | EPS next Y | -1.81 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-26 | ROA | -24.51% |
| ROE | -49.18% | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | -5.68% | Profit Margin | 0.00% | Shs Outstand | 64.75M |
| Shs Float | 51.51M | Short Float | 7.99% | Short Ratio | 1.65 |
| Short Interest | — | 52W High | 3.95 | 52W Low | 1.01 |
| Beta | 1.72 | Avg Volume | 1.32M | Volume | 1.45M |
| Target Price | $5.31 | Recom | Buy | Prev Close | $2.45 |
| Price | $2.47 | Change | 0.82% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$5.31
Mean price target
2. Current target
$2.47
Latest analyst target
3. DCF / Fair value
$-17.43
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.47
Low
$2.00
High
$10.00
Mean
$5.31
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-11-12 | main | Morgan Stanley | Equal-Weight → Equal-Weight | $4 |
| 2025-08-07 | main | Wells Fargo | Equal-Weight → Equal-Weight | $5 |
| 2025-05-15 | reit | Wedbush | Neutral → Neutral | $4 |
| 2025-05-15 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-03-28 | reit | Wedbush | Neutral → Neutral | $4 |
| 2025-03-27 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-03-17 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-01-30 | main | Wells Fargo | Equal-Weight → Equal-Weight | $6 |
| 2025-01-29 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-01-28 | main | UBS | Neutral → Neutral | $2 |
| 2024-11-15 | main | Guggenheim | Buy → Buy | $8 |
| 2024-11-15 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2024-09-16 | reit | Oppenheimer | Outperform → Outperform | $20 |
| 2024-08-12 | up | Wedbush | Underperform → Neutral | $4 |
| 2024-08-12 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2024-06-20 | down | UBS | Buy → Neutral | $5 |
| 2024-06-18 | down | Wells Fargo | Overweight → Equal-Weight | $9 |
| 2024-06-18 | main | Stifel | Buy → Buy | $10 |
| 2024-06-18 | main | HC Wainwright & Co. | Buy → Buy | $20 |
| 2024-06-18 | main | Oppenheimer | Outperform → Outperform | $25 |
- $ZNTL stock is up 11% today. Here's what we see in our data. - Quiver Quantitative hu, 19 Feb 2026 19
- Cancer drug developer Zentalis to speak at three major investor events - Stock Titan Wed, 18 Feb 2026 13
- Zentalis Pharmaceuticals: Hanging On For One Last Shot At PROC Approval (ZNTL) - Seeking Alpha ue, 18 Nov 2025 08
- We're Keeping An Eye On Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Rate - Yahoo Finance Wed, 03 Dec 2025 08
- Walters group buys Zentalis Pharmaceuticals (ZNTL) shares for $7.7m By Investing.com - Investing.com Nigeria hu, 08 Jan 2026 08
- ZNTL Stock Update: Morgan Stanley Lowers Price Target by 50% | Z - GuruFocus Wed, 12 Nov 2025 08
- Zentalis Pharmaceuticals, Inc.'s (NASDAQ:ZNTL) Shares Bounce 28% But Its Business Still Trails The Industry - simplywall.st Wed, 07 Jan 2026 08
- Why ZNTL stock could benefit from AI revolution - Trade Exit Report & Verified Chart Pattern Trade Signals - mfd.ru Sat, 21 Feb 2026 15
- Zentalis outlines 2026 milestones for azenosertib program - The Globe and Mail Sat, 10 Jan 2026 08
- Zentalis Pharmaceuticals Stock (ZNTL) Opinions on Azenosertib Development Update | ZNTL Stock News - Quiver Quantitative Fri, 09 Jan 2026 08
- Following a 13% decline over last year, recent gains may please Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) institutional owners - Yahoo Finance hu, 08 Jan 2026 08
- Zentalis Pharmaceuticals: Late Stage, Lots Of Cash, Crushed By The Market - Seeking Alpha ue, 09 Dec 2025 08
- Does Zentalis (ZNTL) Pairing DENALI Progress With Insider Buying Reveal a Shifting Oncology Strategy? - simplywall.st Sun, 11 Jan 2026 08
- $ZNTL stock is up 28% today. Here's what we see in our data. - Quiver Quantitative ue, 06 Jan 2026 08
- Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) is favoured by institutional owners who hold 59% of the company - Yahoo Finance Wed, 23 Jul 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 40224 | 97557 | — | Sale at price 2.39 - 2.43 per share. | VULTAGGIO VINCENT | Officer | — | 2026-02-10 00:00:00 | D |
| 1 | 3297 | 7998 | — | Sale at price 2.39 - 2.43 per share. | BRUNS INGMAR | Officer | — | 2026-02-09 00:00:00 | D |
| 2 | 8755 | 21239 | — | Sale at price 2.39 - 2.43 per share. | EASTLAND JULIA MARIE | Chief Executive Officer | — | 2026-02-09 00:00:00 | D |
| 3 | 3096 | 7875 | — | Sale at price 2.52 - 2.55 per share. | VULTAGGIO VINCENT | Officer | — | 2026-02-03 00:00:00 | D |
| 4 | 7500000 | 9975000 | — | Sale at price 1.33 per share. | MATRIX CAPITAL MANAGEMENT COMPANY, LP | Beneficial Owner of more than 10% of a Class of Security | — | 2025-12-15 00:00:00 | I |
| 5 | 57603 | — | — | Stock Award(Grant) at price 0.00 per share. | JOHNSON DAVID MICHAEL | Director | — | 2025-06-17 00:00:00 | D |
| 6 | 57603 | — | — | Stock Award(Grant) at price 0.00 per share. | SKVARKA JAN | Director | — | 2025-06-17 00:00:00 | D |
| 7 | 57603 | — | — | Stock Award(Grant) at price 0.00 per share. | KARIUKI ENOCH | Director | — | 2025-06-17 00:00:00 | D |
| 8 | 57603 | — | — | Stock Award(Grant) at price 0.00 per share. | MYERS SCOTT DUNSETH | Director | — | 2025-06-17 00:00:00 | D |
| 9 | 57603 | — | — | Stock Award(Grant) at price 0.00 per share. | WALKER LUKE NATHANIEL | Director | — | 2025-06-17 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 4.57M | -45.90K | 11.97K | 103.97K |
| TaxRateForCalcs | 0.21 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -207.94M | -229.60M | -231.85M | -267.98M |
| TotalUnusualItems | 21.77M | -22.95M | 5.99M | 51.98M |
| TotalUnusualItemsExcludingGoodwill | 21.77M | -22.95M | 5.99M | 51.98M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -165.84M | -292.19M | -236.81M | -158.72M |
| ReconciledDepreciation | 1.29M | 1.39M | 1.43M | 544.00K |
| EBITDA | -186.17M | -252.55M | -225.86M | -216.00M |
| EBIT | -187.46M | -253.94M | -227.29M | -216.54M |
| NormalizedIncome | -183.04M | -269.29M | -242.78M | -210.60M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -165.84M | -292.19M | -236.81M | -158.72M |
| TotalExpenses | 254.88M | 253.94M | 227.29M | 216.54M |
| TotalOperatingIncomeAsReported | -191.19M | -299.51M | -227.29M | -216.54M |
| DilutedAverageShares | 71.08M | 65.41M | 52.86M | 42.69M |
| BasicAverageShares | 71.08M | 65.41M | 52.86M | 42.69M |
| DilutedEPS | -2.33 | -4.47 | -4.48 | -3.72 |
| BasicEPS | -2.33 | -4.47 | -4.48 | -3.72 |
| DilutedNIAvailtoComStockholders | -165.84M | -292.19M | -236.81M | -158.72M |
| NetIncomeCommonStockholders | -165.84M | -292.19M | -236.81M | -158.72M |
| NetIncome | -165.84M | -292.19M | -236.81M | -158.72M |
| MinorityInterests | 28.00K | 114.00K | 307.00K | 7.37M |
| NetIncomeIncludingNoncontrollingInterests | -165.87M | -292.31M | -237.11M | -166.09M |
| NetIncomeContinuousOperations | -165.87M | -292.31M | -237.11M | -166.09M |
| EarningsFromEquityInterestNetOfTax | 0.00 | -16.01M | -16.28M | -1.83M |
| TaxProvision | 177.00K | -601.00K | -469.00K | -297.00K |
| PretaxIncome | -165.69M | -276.89M | -221.30M | -164.56M |
| OtherIncomeExpense | 21.77M | -22.95M | 5.99M | 51.98M |
| SpecialIncomeCharges | -3.74M | -45.57M | 0.00 | 51.58M |
| GainOnSaleOfBusiness | 0.00 | 0.00 | 51.58M | |
| OtherSpecialCharges | 45.57M | |||
| ImpairmentOfCapitalAssets | 3.74M | 0.00 | 0.00 | |
| GainOnSaleOfSecurity | 25.50M | 22.62M | 5.99M | 401.00K |
| OperatingIncome | -187.46M | -253.94M | -227.29M | -216.54M |
| OperatingExpense | 254.88M | 253.94M | 227.29M | 216.54M |
| ResearchAndDevelopment | 167.77M | 189.59M | 172.73M | 175.60M |
| SellingGeneralAndAdministration | 87.11M | 64.35M | 54.55M | 40.94M |
| GeneralAndAdministrativeExpense | 87.11M | 64.35M | 54.55M | 40.94M |
| OtherGandA | 87.11M | 64.35M | 54.55M | 40.94M |
| TotalRevenue | 67.42M | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 67.42M | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 71.28M | 70.77M | 59.28M | 45.49M |
| ShareIssued | 71.28M | 70.77M | 59.28M | 45.49M |
| TotalDebt | 39.58M | 43.15M | 45.17M | 44.46M |
| TangibleBookValue | 337.19M | 433.55M | 430.07M | 360.22M |
| InvestedCapital | 337.19M | 437.28M | 433.80M | 363.95M |
| WorkingCapital | 333.34M | 427.35M | 395.29M | 306.83M |
| NetTangibleAssets | 337.19M | 433.55M | 430.07M | 360.22M |
| CapitalLeaseObligations | 39.58M | 43.15M | 45.17M | 44.46M |
| CommonStockEquity | 337.19M | 437.28M | 433.80M | 363.95M |
| TotalCapitalization | 337.19M | 437.28M | 433.80M | 363.95M |
| TotalEquityGrossMinorityInterest | 337.19M | 437.39M | 434.02M | 364.48M |
| MinorityInterest | 0.00 | 107.00K | 221.00K | 528.00K |
| StockholdersEquity | 337.19M | 437.28M | 433.80M | 363.95M |
| GainsLossesNotAffectingRetainedEarnings | 558.00K | 2.19M | -1.35M | -125.00K |
| OtherEquityAdjustments | 558.00K | 2.19M | -1.35M | -125.00K |
| RetainedEarnings | -1.05B | -888.56M | -596.37M | -359.56M |
| AdditionalPaidInCapital | 1.39B | 1.32B | 1.03B | 723.59M |
| CapitalStock | 71.00K | 70.00K | 59.00K | 45.00K |
| CommonStock | 71.00K | 70.00K | 59.00K | 45.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 93.15M | 114.30M | 105.29M | 90.03M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 40.43M | 44.93M | 48.64M | 46.08M |
| OtherNonCurrentLiabilities | 849.00K | 1.78M | 2.62M | |
| NonCurrentDeferredLiabilities | 0.00 | 853.00K | 1.62M | |
| NonCurrentDeferredTaxesLiabilities | 0.00 | 853.00K | 1.62M | |
| LongTermDebtAndCapitalLeaseObligation | 39.58M | 43.15M | 45.17M | 44.46M |
| LongTermCapitalLeaseObligation | 39.58M | 43.15M | 45.17M | 44.46M |
| CurrentLiabilities | 52.73M | 69.37M | 56.65M | 43.94M |
| CurrentDebtAndCapitalLeaseObligation | 1.45M | |||
| CurrentCapitalLeaseObligation | 1.45M | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 9.25M | |||
| PayablesAndAccruedExpenses | 52.73M | 69.37M | 56.65M | 43.94M |
| CurrentAccruedExpenses | 45.29M | 54.44M | 45.40M | 32.35M |
| Payables | 7.44M | 14.93M | 11.25M | 11.59M |
| TotalTaxPayable | 971.00K | |||
| IncomeTaxPayable | 971.00K | |||
| AccountsPayable | 7.44M | 14.93M | 11.25M | 11.59M |
| TotalAssets | 430.34M | 551.69M | 539.31M | 454.51M |
| TotalNonCurrentAssets | 44.27M | 54.97M | 87.38M | 103.74M |
| OtherNonCurrentAssets | 7.04M | 9.50M | 12.35M | 9.67M |
| NonCurrentPrepaidAssets | 9.72M | 7.04M | ||
| InvestmentsAndAdvances | 0.00 | 21.21M | 37.49M | |
| LongTermEquityInvestment | 0.00 | 21.21M | 37.49M | |
| InvestmentsinJointVenturesatCost | 21.21M | 37.49M | ||
| InvestmentsinAssociatesatCost | 0.00 | 21.21M | 37.49M | |
| GoodwillAndOtherIntangibleAssets | 0.00 | 3.74M | 3.74M | 3.74M |
| Goodwill | 0.00 | 3.74M | 3.74M | 3.74M |
| NetPPE | 37.23M | 41.73M | 50.08M | 52.84M |
| AccumulatedDepreciation | -4.27M | -3.15M | -2.06M | -792.00K |
| GrossPPE | 41.50M | 44.88M | 52.14M | 53.63M |
| Leases | 4.17M | 4.24M | 4.89M | 4.51M |
| ConstructionInProgress | 0.00 | 173.00K | 37.00K | 34.00K |
| OtherProperties | 35.91M | 38.98M | 44.99M | 46.75M |
| MachineryFurnitureEquipment | 1.42M | 1.49M | 2.21M | 2.33M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 386.07M | 496.72M | 451.93M | 350.77M |
| OtherCurrentAssets | 9.98M | 13.80M | 14.56M | 10.64M |
| RestrictedCash | 0.00 | 243.00K | ||
| PrepaidAssets | 14.56M | 10.64M | ||
| Receivables | 5.00M | 0.00 | 7.04M | 4.44M |
| OtherReceivables | 5.00M | 6.53M | 4.18M | |
| AccruedInterestReceivable | 508.00K | 258.00K | ||
| AccountsReceivable | 4.00K | |||
| CashCashEquivalentsAndShortTermInvestments | 371.08M | 482.92M | 437.37M | 339.89M |
| OtherShortTermInvestments | 337.18M | 454.88M | 394.30M | 280.17M |
| CashAndCashEquivalents | 33.90M | 28.04M | 43.07M | 59.71M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -171.08M | -208.41M | -166.30M | -160.20M |
| IssuanceOfCapitalStock | 349.00K | 237.30M | 261.04M | 179.67M |
| CapitalExpenditure | -221.00K | -583.00K | -2.55M | -6.11M |
| IncomeTaxPaidSupplementalData | 359.00K | 140.00K | 12.00K | 20.00K |
| EndCashPosition | 36.53M | 30.72M | 45.70M | 62.58M |
| BeginningCashPosition | 30.72M | 45.70M | 62.58M | 56.27M |
| ChangesInCash | 5.81M | -14.98M | -16.89M | 6.31M |
| FinancingCashFlow | 108.00K | 237.30M | 261.04M | 178.52M |
| CashFlowFromContinuingFinancingActivities | 108.00K | 237.30M | 261.04M | 178.52M |
| NetOtherFinancingCharges | -241.00K | -1.15M | ||
| NetPreferredStockIssuance | 0.00 | 0.00 | ||
| PreferredStockIssuance | 0.00 | 0.00 | ||
| NetCommonStockIssuance | 349.00K | 237.30M | 261.04M | 179.67M |
| CommonStockIssuance | 349.00K | 237.30M | 261.04M | 179.67M |
| InvestingCashFlow | 176.56M | -44.46M | -114.18M | -18.11M |
| CashFlowFromContinuingInvestingActivities | 176.56M | -44.46M | -114.18M | -18.11M |
| NetInvestmentPurchaseAndSale | 176.72M | -43.88M | -111.63M | 2.31M |
| SaleOfInvestment | 304.68M | 505.31M | 421.53M | 365.82M |
| PurchaseOfInvestment | -127.96M | -549.18M | -533.16M | -363.51M |
| NetBusinessPurchaseAndSale | 0.00 | 0.00 | -14.32M | |
| PurchaseOfBusiness | 0.00 | 0.00 | -14.32M | |
| NetPPEPurchaseAndSale | -156.00K | -583.00K | -2.55M | -6.11M |
| SaleOfPPE | 65.00K | 0.00 | 0.00 | |
| PurchaseOfPPE | -221.00K | -583.00K | -2.55M | -6.11M |
| OperatingCashFlow | -170.86M | -207.82M | -163.75M | -154.09M |
| CashFlowFromContinuingOperatingActivities | -170.86M | -207.82M | -163.75M | -154.09M |
| ChangeInWorkingCapital | -16.54M | 5.86M | 13.25M | 16.61M |
| ChangeInOtherWorkingCapital | 264.00K | 623.00K | 4.33M | 1.35M |
| ChangeInPayablesAndAccruedExpense | -18.02M | 10.92M | 15.53M | 13.96M |
| ChangeInPayable | -18.02M | 10.92M | 15.53M | 13.96M |
| ChangeInAccountPayable | -18.02M | 10.92M | 15.53M | 13.96M |
| ChangeInPrepaidAssets | 6.22M | -5.68M | -6.61M | 1.29M |
| ChangeInReceivables | -5.00M | 0.00 | 0.00 | 413.00K |
| ChangesInAccountReceivables | -5.00M | 0.00 | 0.00 | 413.00K |
| OtherNonCashItems | -47.42M | 15.04M | ||
| StockBasedCompensation | 67.27M | 54.82M | 46.84M | 35.74M |
| UnrealizedGainLossOnInvestmentSecurities | -5.23M | 0.00 | 0.00 | |
| AssetImpairmentCharge | 3.74M | 4.95M | 0.00 | 8.80M |
| AmortizationOfSecurities | -8.00M | -13.16M | -3.73M | 908.00K |
| DeferredTax | 0.00 | -853.00K | -769.00K | -2.51M |
| DeferredIncomeTax | 0.00 | -853.00K | -769.00K | -2.51M |
| DepreciationAmortizationDepletion | 1.29M | 1.39M | 1.43M | 544.00K |
| DepreciationAndAmortization | 1.29M | 1.39M | 1.43M | 544.00K |
| OperatingGainsLosses | -92.00K | 16.42M | 16.34M | -48.08M |
| EarningsLossesFromEquityInvestments | 0.00 | 16.01M | 16.28M | 1.83M |
| GainLossOnSaleOfPPE | -13.00K | 406.00K | 56.00K | 15.00K |
| GainLossOnSaleOfBusiness | -79.00K | 0.00 | 0.00 | -49.93M |
| NetIncomeFromContinuingOperations | -165.87M | -292.31M | -237.11M | -166.09M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ZNTL
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|